Strategic Alliance Between Apertura and Viralgen to Advance Gene Therapy Manufacturing Apertura Gene Therapy and Viralgen have partnered to manufacture TfR1 CapX, a breakthrough capsid for gene therapies aimed at central nervous system diseases.

Strategic Alliance Between Apertura and Viralgen to Advance Gene Therapy Manufacturing #USA #New_York #Viralgen #Apertura_Gene_Therapy #TfR1_CapX

Apertura Gene Therapy and Viralgen Unite for Advanced Gene Therapy Manufacturing Apertura Gene Therapy teams up with Viralgen to manufacture the innovative TfR1 CapX for treating central nervous system diseases, enhancing gene therapy prospects.

Apertura Gene Therapy and Viralgen Unite for Advanced Gene Therapy Manufacturing #USA #New_York #Viralgen #Apertura_Gene_Therapy #TfR1_CapX

Apertura Gene Therapy and Viralgen Team Up for Innovative Gene Therapy Development Apertura and Viralgen forge a strategic partnership to manufacture the new TfR1 CapX capsid, enhancing gene therapies for central nervous system diseases.

Apertura Gene Therapy and Viralgen Team Up for Innovative Gene Therapy Development #USA #New_York #Viralgen #Apertura_Gene_Therapy #TfR1_CapX

Viralgen Enters Clinical Development Network to Tackle Rare Diseases Viralgen partners with Orphan Therapeutics Accelerator to enhance AAV gene therapy efforts for ultra-rare diseases, aiming to streamline manufacturing processes.

Viralgen Enters Clinical Development Network to Tackle Rare Diseases #Spain #San_Sebastián #Viralgen #AAV_Gene_Therapy #Orphan_Therapeutics_Accelerator

Viralgen Partners with Trogenix to Propel AAV Gene Therapy for Glioblastoma Viralgen joins forces with Trogenix to advance AAV gene therapy for glioblastoma, enhancing manufacturing and accelerating clinical trials.

Viralgen Partners with Trogenix to Propel AAV Gene Therapy for Glioblastoma #Spain #San_Sebastián #Viralgen #AAV_Gene_Therapy #Trogenix

Innovative Gene Therapy for CTNNB1 Syndrome: A Partnership by Viralgen and CTNNB1 Foundation Viralgen has teamed up with the CTNNB1 Foundation to create a groundbreaking gene therapy for CTNNB1 Syndrome, promising hope to patients worldwide.

Innovative Gene Therapy for CTNNB1 Syndrome: A Partnership by Viralgen and CTNNB1 Foundation #Spain #San_Sebastián #Viralgen #CTNNB1_Syndrome #CTNNB1_Foundation

Viralgen and Axovia Join Forces for Gene Therapy Development for Retinal Dystrophy Viralgen and Axovia are collaborating to manufacture an investigational gene therapy targeting retinal dystrophy in Bardet-Biedl Syndrome patients.

Viralgen and Axovia Join Forces for Gene Therapy Development for Retinal Dystrophy #Spain #San_Sebastián #Viralgen #Axovia #BBS